Navigation Links
Renova Therapeutics appoints Richard 'Mac' McCloskey to head company's clinical development efforts
Date:1/14/2016

SAN DIEGO, Jan. 14, 2016 /PRNewswire-USNewswire/ -- Renova™ Therapeutics, a biopharmaceutical company developing gene therapy treatments for congestive heart failure and other chronic diseases, has hired Richard 'Mac' McCloskey, M.D., as Executive Vice President of Clinical Development.

An author of more than 100 peer-reviewed papers and editorials as well as three books, Dr. McCloskey has led an illustrious career in medical research and clinical practice. He has directed registration trials for Hoffman LaRoche and Centocor and was, most recently, Vice President of Scientific Affairs at Johnson & Johnson Development Corporation as well as a scientific adviser to Endo Pharmaceuticals.

Richard 'Mac' McCloskey, MD, joins Renova Therapeutics as Executive Vice President of Clinical Development.
Richard 'Mac' McCloskey, MD, joins Renova Therapeutics as Executive Vice President of Clinical Development.

As Executive Vice President of Clinical Development for Renova Therapeutics, Dr. McCloskey will be responsible for all clinical aspects of the company's trials, including preparation of trial synopses and protocols, review and approval of case report systems and safety reporting, and drafting of clinical trial endpoints. He will also ensure Renova Therapeutics meets all regulatory requirements for clinical trial safety reporting, and, as needed, will present trial data to regulatory agencies.

In this role, Dr. McCloskey will work closely with the Senior Vice President of Regulatory Affairs and Quality Assurance and will coordinate with the company's expert consultants on statistical analysis, trial planning and conduct. His immediate focus will be on Renova Therapeutics' lead investigational product RT-100, a single-dose gene therapy for the treatment of congestive heart failure, which recently completed a Phase 2 clinical trial.

"We're excited to have Mac join Renova as we progress further with our product pipeline," said Jack W. Reich, Ph.D., CEO and Co-founder of Renova Therapeutics. "His contributions in the medical field and in clinical development will be a tremendous asset to our team, as we continue to develop a portfolio of gene therapies for cardiovascular and metabolic diseases."

Dr. McCloskey received a master's in microbiology and an M.D. from the University of Rochester and completed his medical training at Duke University and the National Institutes of Health. He has been on the faculty of the University of Texas, the University of Pennsylvania and Jefferson Medical College, and he is an emeritus fellow of the American College of Physicians and the Infectious Disease Society of America.

His FDA-approved submissions include interferon, ceftriaxone, infliximab, abciximab, midazolam and injectable testosterone. He also contributed to the following as an academic clinical investigator: cefoxitin, thienamycin, cefotaxime, mezlocillin, ticarcillin, imipenem-cilastatin, cefmenoxime, amdinocillin, fleroxacin and ofloxacin.

To him, taking on this role is personal: "Having been treated for congestive heart failure by the single procedure of surgical aortic valve replacement, I have both a personal and scientific appreciation of the breakthrough potential of a single treatment for CHF," says McCloskey. "And the data derived so far for RT-100 demonstrates that potential."

About Renova Therapeutics
Renova™ Therapeutics is developing definitive, one-time gene therapy treatments to restore the health of people suffering from chronic diseases. The first two indications the company is pursuing are therapies for congestive heart failure (CHF) and type 2 diabetes, two of the most common and devastating chronic diseases in the world. The company's lead investigational product, RT-100, is a new type of treatment that delivers a therapeutic gene directly to damaged heart tissue during a routine outpatient procedure and has the potential to renew heart function in millions of patients with CHF. The company's product pipeline also includes a second-generation therapy for CHF patients and a groundbreaking therapy in pre-clinical stage for sufferers of type 2 diabetes. Renova Therapeutics was founded in 2009 and is led by an experienced management team in biopharmaceuticals and gene therapy. For additional information about the company, please visit www.renovatherapeutics.com.

Photo - http://photos.prnewswire.com/prnh/20160112/321689
Logo - http://photos.prnewswire.com/prnh/20151231/318660LOGO


'/>"/>
SOURCE Renova Therapeutics
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round
2. ViveBio, LLC Enters Worldwide Exclusive Licensing Agreement with Renovar Inc. for Novel Urine Based Biomarker Technologies Covering Kidney Disease and Transplant Monitoring
3. Renova Therapeutics recruits seasoned expert to lead companys regulatory and quality efforts
4. Renova Therapeutics expands robust gene therapy intellectual property portfolio for cardiovascular and metabolic disease treatments
5. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
6. Novelos Therapeutics Provides Product Pipeline Update
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
8. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
9. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
10. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
11. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2019)... ... September 18, 2019 , ... Lake Minnetonka ... the launch of its new Hybrid-Responsive™ website: https://www.lakeminnetonkaortho.com . , The ... that allows patients to interact with the practice more easily online. Improvements include ...
(Date:9/18/2019)... (PRWEB) , ... September 18, ... ... parent organization to ReachMD, Global Learning Collaborative, and other healthcare-focused subsidiaries, today ... environment, DecisionSim™, uses real-world cases to challenge healthcare professionals (HCPs) to make ...
(Date:9/18/2019)... ... , ... The interns of NJ Lenders Corp. recently spent their time giving ... (YCS) in Hackensack , where NJ Lenders donated $1,000 worth of school supplies for ... a pizza party and handed out ice cream. , NJ Lenders is a part ...
Breaking Medicine Technology:
(Date:9/18/2019)... ... ... DOROT hosts its annual Rosh Hashanah Package delivery on Sunday, September 22nd at 10 am. ... out to visit our seniors. , , The Upper West Side ... Synagogue 123 East 55st Street , & Westchester at Young Israel of Scarsdale ...
(Date:9/17/2019)... (PRWEB) , ... September 17, 2019 , ... Milwaukee-area dealership Hall Cars has hosted an ... affected by cancer. The event, entitled “Drive Out Cancer,” entails that for every vehicle purchased ... Tomorrow Foundation. As the event lasts for 50 days, it has also been referred to ...
(Date:9/17/2019)... , ... September 17, 2019 , ... ... for Europe and the 21st Century Cures Act in the US, Nocimed has ... and pain management. Using images from existing MRI equipment to perform MR ...
(Date:9/17/2019)... ... September 17, 2019 , ... Drs. Charles Felts and ... teeth in Chattanooga, TN for customized full mouth dental implants with TeethXpress® ... one day, providing a permanent tooth replacement solution for patients who struggle with ...
(Date:9/17/2019)... , ... September 17, 2019 , ... Lubin Austermuehle, ... fundraiser. Gather for GRIN2B will be held at Found Kitchen and Social ... Proceeds will help fund research on GRIN2B-Related Neurodevelopmental Disorder, a rare condition that results ...
Breaking Medicine News(10 mins):